Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation

Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation

Limited studies have investigated population pharmacokinetic (PK) models and optimal dosage regimens of meropenem for critically ill adult patients using the probability of target attainment, including patients receiving extracorporeal membrane oxygenation (ECMO). A population PK analysis was conduc...

Full description

Bibliographic Details
Main Authors:	Dong-Hwan Lee, Hyoung-Soo Kim, Sunghoon Park, Hwan-il Kim, Sun-Hee Lee, Yong-Kyun Kim
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Series:	Pharmaceutics
Subjects:	meropenem population pharmacokinetics critically ill patient adult extracorporeal membrane oxygenation Monte Carlo simulation
Online Access:	https://www.mdpi.com/1999-4923/13/11/1861

Similar Items

Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation
by: Jae Ha Lee, et al.
Published: (2021-11-01)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
by: Matthias Gijsen, et al.
Published: (2021-06-01)

Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling
by: Soyoung Kang, et al.
Published: (2022-11-01)

Population pharmacokinetics of meropenem in critically ill infant patients
by: Wanlika Yonwises, et al.
Published: (2021-10-01)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
by: Gan Y, et al.
Published: (2023-06-01)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
by: Renata Černá Pařízková, et al.
Published: (2021-07-01)

Meropenem extraction by ex vivo extracorporeal life support circuits
by: Honeycutt Christopher Cole, et al.
Published: (2023-12-01)

Pharmacokinetics Alterations in Critically Ill Pediatric Patients on Extracorporeal Membrane Oxygenation: A Systematic Review
by: Natalia Sutiman, et al.
Published: (2020-06-01)

External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients
by: Nan Yang, et al.
Published: (2022-05-01)

Evaluation of Meropenem Pharmacokinetics in an Experimental Acute Respiratory Distress Syndrome (ARDS) Model during Extracorporeal Membrane Oxygenation (ECMO) by Using a PenP β-Lactamase Biosensor
by: Max Andresen, et al.
Published: (2018-05-01)

Optimized Dosing Regimens of Meropenem in Septic Children Receiving Extracorporeal Life Support
by: Yixue Wang, et al.
Published: (2021-08-01)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
by: Sonia Luque, et al.
Published: (2021-06-01)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
by: Eric Wenzler, et al.
Published: (2020-10-01)

The Influence of Extracorporeal Membrane Oxygenation on Antibiotic Pharmacokinetics
by: Gregory J. Peitz, et al.
Published: (2023-03-01)

Impaired Pharmacokinetics of Amiodarone under Veno-Venous Extracorporeal Membrane Oxygenation: From Bench to Bedside
by: Mickaël Lescroart, et al.
Published: (2022-04-01)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
by: Ahmed A. Abulfathi, et al.
Published: (2021-06-01)

Population pharmacokinetics of tigecycline in critically ill patients
by: Xiangru Luo, et al.
Published: (2023-03-01)

Meropenem pharmacokinetics during relapsing peritonitis due to ESBL‐producing Enterobacteriaciae in a liver transplant recipient
by: Kensuke Shoji, et al.
Published: (2019-11-01)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
by: Guoliang Deng, et al.
Published: (2023-03-01)

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis
by: Yue-E Wu, et al.
Published: (2022-12-01)

Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?
by: Silvia Corcione, et al.
Published: (2020-03-01)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
by: Christina Scharf, et al.
Published: (2020-03-01)

Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization
by: Pier Giorgio Cojutti, et al.
Published: (2021-12-01)

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study
by: Stephan Braune, et al.
Published: (2018-01-01)

Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
by: Jörn Grensemann, et al.
Published: (2020-04-01)

Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study
by: Hui-Ying Zhao, et al.
Published: (2017-01-01)

Effects of Meropenem on Patients with Ventilator-Induced Pneumonia in Intensive Care Unit
by: Taraneh Naghibi, et al.
Published: (2022-11-01)

Relationship between Target Time above Minimum Inhibitory Concentration Achievement Rate of Meropenem Using Monte Carlo Simulation and In-Hospital Survival in Patients with <i>Pseudomonas aeruginosa</i> Bacteremia
by: Hajime Nakashima, et al.
Published: (2024-02-01)

Therapeutic drug monitoring of meropenem and pharmacokinetic-pharmacodynamic target assessment in critically ill pediatric patients from a prospective observational study
by: Passara Maimongkol, et al.
Published: (2022-07-01)

Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools
by: Ferdinand Anton Weinelt, et al.
Published: (2022-06-01)

Comparison of Intravenous Microdialysis and Standard Plasma Sampling for Monitoring of Vancomycin and Meropenem Plasma Concentrations—An Experimental Porcine Study
by: Johanne Gade Lilleøre, et al.
Published: (2023-04-01)

Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation
by: Claire Pressiat, et al.
Published: (2022-01-01)

PHARMACOKINETIC-PHARMACODYNAMIC CORRELATION FOR MEROPENEM APPLIED TO A BURN CHILD USING A BIOANALYTICAL LIQUID CROMATOGRAPHIC METHOD
by: Silvia R. C. J. Santos, et al.
Published: (2011-12-01)

Pharmacokinetic-Pharmacodynamic Correlation for Meropenem Applied to a Burn Child Using a Bioanalytical Liquid Cromatographic Method
by: Silvia R. C. J. Santos, et al.
Published: (2011-10-01)

Pharmacokinetics of vancomycin in adults receiving extracorporeal membrane oxygenation
by: Chien-Chih Wu, et al.
Published: (2016-07-01)

Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and <i>P. aeruginosa</i>
by: Pier Giorgio Cojutti, et al.
Published: (2020-08-01)

Blood Transfusion Strategies in Patients Undergoing Extracorporeal Membrane Oxygenation
by: Hyoung Soo Kim, et al.
Published: (2017-02-01)

Improving the efficacy for meropenem therapy requires a high probability of target attainment in critically ill infants and children
by: Zeming Wang, et al.
Published: (2022-10-01)

Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients—A Controlled Clinical Trial
by: Philipp Simon, et al.
Published: (2020-12-01)

Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria
by: Amol T. Kothekar, et al.
Published: (2020-01-01)